HOPE-BP 2.0: Evaluating the Optimal Duration of Postpartum Remote Blood Pressure Monitoring

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18+
SponsorUniversity of Minnesota

About this trial

Postpartum remote blood pressure monitoring programs for patients with hypertensive disorders of pregnancy (HDP) are becoming part of standard postpartum management. Existing programs range in duration from 2 to 6 weeks but there has not been any evaluation as to what program duration is optimal. The primary objective of this study is to evaluate the impact of program duration on clinical outcomes for patients participating in a single institution's postpartum remote blood pressure monitoring program for patients with HDP.

Eligibility criteria

Qualifiers

18 years or older

Discharged after delivery at University of Minnesota Medical Center

Enrolled into the HOPE-BP Program

Disqualifiers

Ongoing antihypertensive medication use at 2 weeks (time of randomization)

Have a medical comorbidity that would not be clinically appropriate to randomize

Patients opted out of clinical research

Trial design

Treatments tested in this trial

  • 2-Week Home Monitoring
  • 6-Week Home Monitoring

Treatment groups

400 Participants
are divided into 2 treatment groups

Locations

1
University of Minnesota55455, MinneapolisMinnesota, United States

Sponsors and collaborators

University of Minnesota

Lead sponsor